Asclepius Life Sciences Hosts Investor Forum – January 16, 2017 | South Florida

Opportunity with Asclepius Life Sciences Fund LP

Asclepius Life Sciences Hosts Investor Forum

Investing in Life Sciences:  Distinctive Opportunities in the Public & Private Markets


On January 16, 2017, Asclepius Life Sciences is proud to host a private investor forum in South Florida to discuss investment opportunities currently present within the Life Sciences sector.  The event is by invitation only to a prominent group of investors.

Attendees will hear from the Asclepius Life Sciences Fund, L.P. senior management team including Michael J. Levas (Co-Founder, Senior Managing Principal & Chief Investment Officer), Steve Glover (Co-Founder & Managing Principal) and Dr. Steven Gerst (Co-Founder & Principal).  They will highlight:

  • Why the global pharmaceutical industry is entering a new paradigm for growth.
  • How significant structural challenges are creating volatility and trading opportunities in the public markets.
  • How new business models, ‘beyond the pill’ outcomes, and real-world data are providing health data and transforming what is possible.

The investor forum will include company specific presentations and discussions led by the senior management teams of distinguished pharmaceutical and biotechnology companies.


About Asclepius Life Sciences Fund , L.P.

Asclepius Life Sciences Fund, L.P.  is focused on robust investment opportunities present in the life sciences sector including healthcare, pharmaceuticals, agriculture, personal care, biosciences and biotechnology companies.  Asclepius’s senior management has created and assembled a veteran team with a proven track record in investment management and life sciences; spanning hedge fund, Fortune 100 and start-up environments with M&A transactions exceeding $10 billion.  The team has deep experience in several  therapeutic classes of pharmaceuticals and biopharmaceuticals, including strategic planning, corporate development, operations management, product development, clinical and regulatory, product marketing and sales management on a global basis.

The Fund’s investment analysis is focused on unmet medical needs, scientific due diligence, commercial viability, risk-adjusted NPV, management competency and liquidity.  Through a nationally recognized professional team, and within a Master Feeder construct, Asclepius employs a multi-asset class approach to the life sciences sector in order to provide absolute returns within a risk managed framework.

For investor and media inquires, please contact Eric Dansky, Associate Director of Family Office Investor Relations at edansky (at) asclepiuslifesciences.com.


 

| Accredited Investors

The information contained in this web site has been prepared solely for accredited investors. It is for informational purposes and is not an offer to sell or purchase or a solicitation of an offer to sell or purchase any interests or shares in any of the funds managed by Asclepius Investment Strategies, LLC Such offers are made only by way of a private offering memorandum delivered to qualified investors.

| Contact

ASCLEPIUS LIFE SCIENCES FUND, L.P.
641 Lexington Avenue, Suite 1337
New York, NY 10022
Phone: (212) 634-6440
Fax: (212) 634-6480